NCT01536704View on ClinicalTrials.gov

Nicotine Lozenge Bioequivalence Study

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Smoking Cessation

Interventions

DRUG

Nicotine (2 mg)

2 mg nicotine lozenge in two formulations

DRUG

Nicotine (4 mg)

4 mg nicotine lozenge in two formulations

Trial Locations (1)

68502

Celerion NEBRASKA, Lincoln

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01536704 - Nicotine Lozenge Bioequivalence Study | Biotech Hunter | Biotech Hunter